Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on RAVEN RUSSIA LTD. We currently have 25 research reports from 4 professional analysts.
|09Feb17 07:00||RNS||Preference Share Dividend|
|02Feb17 07:00||RNS||Block listing Interim Review|
|25Jan17 07:00||RNS||Director Declaration|
|19Jan17 16:30||RNS||Acquisition and Notice of Results|
|03Jan17 07:05||RNS||Director/PDMR Shareholding|
|03Jan17 07:00||RNS||Total Voting Rights|
|30Dec16 07:00||RNS||Issue of Preference Shares|
Frequency of research reports
Research reports on
RAVEN RUSSIA LTD
RAVEN RUSSIA LTD
An opportune acquisition
24 Jan 17
Raven has announced the conditional acquisition of three properties in St Petersburg for RUB4.9bn (c $82m), below their replacement cost, which will generate rent of $13m in the first year of ownership (c 16% initial yield). The acquisition will be funded from existing cash reserves and is expected to be complete by the end of February. We maintain our previous forecasts pending the completion of the acquisition and the publication of Raven’s FY16 results on 13 March 2017.
N+1 Singer - Morning Song 20-01-2017
20 Jan 17
Abzena (ABZA LN) ThioBridge™ licensing deal demonstrates technology leadership | Halfords Group (HFD LN) Positive lead indicators + FX mitigation progress | Midatech Pharma (MTPH LN) FY trading update: revenue ahead of estimates | MySale Group (MYSL LN) Strong progress in H1; positive momentum bodes well for H2 | PCI-PAL (PCIP LN) H1 revenue slightly ahead, CFO stepping down | Raven Russia Ltd (RUS LN) A step forward | SDL (SDL LN) Transformation progressing well | Synthomer (SYNT LN) Positive trading update and forecast upgrade
N+1 Singer - Raven Russia Ltd - A step forward…
19 Jan 17
An opportunistic acquisition of quality assets in St Petersburg on a highly attractive initial yield of 16% is exactly the sort of transaction envisaged when Raven Russia strengthened its balance sheet last Summer. While the Russian macro background and general investment sentiment towards the country continues to improve, this has yet to make itself obvious in the warehouse letting market, although this seems likely, in our view, to be only a matter of time. In the meantime the near 20% discount to NAV gives the shares a firm underpinning.
N+1 Singer - Small-cap quantitative research - Re-run of the value screen and 9 focus stocks
10 Nov 16
We have completed another periodic refresh of our value style screen, first established in our note of 26 May 2015. As usual the screen selected the 25 stocks exhibiting the most extreme value characteristics from our universe, and we have chosen 9 stocks to focus on. Since inception last year the screen has marginally outperformed the main small-cap index by 1pp and underperformed the micro-cap index by about 3pp. The EU referendum result arose in the latest period and resulted in significant short-term underperformance, which has not been recovered. The new basket was struck before the US election result.
Robust performance and financial strength
31 Aug 16
Market conditions, echoing economic developments, show signs of stabilising and occupancy levels have held at 82% over the period, in line with our forecast. The company’s active leasing efforts, aimed at defending income and cash flow, have dealt with the majority of the 2016 lease maturities. Costs are being contained and the cash balance has remained strong even before July’s £109m issue of convertible preference shares. Raven is well placed to navigate current market conditions and seize opportunities in an upturn.
21 Feb 17
Lighthouse Group* (LGT): Middle Britain growth (CORP) | Utilitywise* (UTW): Double-digit sales growth (CORP) | Trakm8* (TRAK): Earnings expectations cut again (CORP) | dotDigital* (DOTC): Myriad growth opportunities (CORP) | Artilium* (ARTA): Five-year Telenet deal secured and prepaid (CORP) | Netcall* (NET): Cloud investment pays off (CORP)
Industry fundamentals remain positive
21 Feb 17
The Biotech Growth Trust (BIOG) is a specialist vehicle, aiming to generate long-term capital growth via investment in global biotech stocks. Following a particularly volatile period for the biotech industry, where concerns about drug pricing and investor risk aversion have weighed heavily on stock prices, the managers are hopeful that greater clarity regarding US healthcare policy will lead to continued improved performance of biotech stocks. Industry fundamentals remain attractive, including continued innovation and valuations are very supportive, which offers the potential for higher industry merger and acquisition activity.
Small Cap Breakfast
16 Feb 17
Saffron Energy—Schedule One update. Raising £2.5m, expected Mkt Cap £7.7m. Admission due 24 Feb. Italian Oil & Gas Play Guinness Oil & Gas Exploration—Publication of prospectus. Seeking to raise £50m and invest in 15 exploration companies at launch, with plans to grow the portfolio to 30 positions during its lifetime. Issue closing 23 Feb. Arix Bioscience — Intention to float on the main market from the global healthcare and life science Company supporting medical innovation. Raised £52m in Feb 16 with investors including Woodford Investment Management
13 Feb 17
Surface Transforms* (SCE): H1 results confirm operational progress (CORP) | Premaitha Health* (NIPT): European diagnostics partnership (CORP) | Lok'nStore* (LOK): Filling existing stores, developing new ones (CORP) | Victoria* (VCP): Entry into the European flooring market (CORP) | eg solutions* (EGS): Exceptional H2 performance (CORP)
Middle Britain growth
21 Feb 17
The Company has achieved our 2017 estimate in 2016 with EBITDA of £2.2m, up 37% on 2015. We upgrade our estimates by 10% at the EBITDA level in 2017. If the shares traded even at the lower end of comparators, they would trade at 17p. We expect the share price to reach our upgraded 17p price target in the short term. Few companies enjoy the unique positioning which Lighthouse has to benefit from the assets of Middle Britain.
Share & share alike
14 Feb 17
The rally in the last fortnight, highlighted in the table, reflects a continued flow of positive updates and economic news. The FTSE 250, Small cap and Fledgling indices have reached record highs. We are in the lull ahead of results for those companies with a December year end, a welter of economic data regarding the UK economy, the State of the Union address in the US on 28 February and the UK Budget on Wednesday 8 March. We will learn at that stage the latest forecasts from the Office of Budget Responsibility. As highlighted previously, the reaction to corporate updates will continue to set the tone.